Kim Y-E, Woo H I, On Y K, Kim J S, Lee S-Y
Departments of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Departments of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Eur J Clin Nutr. 2015 Jun;69(6):703-6. doi: 10.1038/ejcn.2015.41. Epub 2015 Apr 1.
BACKGROUND/OBJECTIVES: Vitamin K intake is considered as a controllable contributor to warfarin sensitivity. It is restricted in warfarin-treated patients. However, little study has assessed the vitamin K status in warfarin-treated patients. We directly measured plasma vitamin K in warfarin-treated patients and evaluated its effect on anticoagulation.
SUBJECTS/METHODS: A total of 302 plasma vitamin K concentrations were assessed using high-performance liquid chromatography for 203 outpatients with atrial fibrillation under warfarin treatment. Clinical and laboratory information including warfarin dosage, plasma warfarin concentrations, prothrombin time international normalized ratio (PT INR) and CYP2C9/VKORC1 genotypes was reviewed retrospectively. The anticoagulation stability (intra-individual variability, frequency of PT INR tests and complications) was investigated in 163 patients with long-term warfarin therapy. Plasma vitamin K was measured in 40 healthy subjects and in 40 patients before and after initial warfarin treatment.
Vitamin K concentrations were significantly decreased after the initiation of warfarin treatment (before treatment: 1.72 ng/ml; after treatment: 0.59 ng/ml, P<0.05). There was a large inter-individual variability in vitamin K levels (0.2-4.2 ng/ml) in warfarin-treated patients. PT INR was more frequently checked in patients with low plasma vitamin K levels than in those with high vitamin K levels (9.5 times/year vs 7.5 times/year, P=0.029). Two patients with gross hematuria showed very low vitamin K levels (<0.4 ng/ml).
We found high inter- and intra-individual variability in vitamin K concentration in warfarin-treated patients. Low vitamin K concentration in warfarin-treated patients suggested excessive dietary restriction. Plasma vitamin K measurement would be helpful for dietary control and anticoagulation stability.
背景/目的:维生素K摄入量被认为是影响华法林敏感性的一个可控因素。在接受华法林治疗的患者中,维生素K的摄入受到限制。然而,很少有研究评估接受华法林治疗患者的维生素K状态。我们直接测定了接受华法林治疗患者的血浆维生素K水平,并评估了其对抗凝作用的影响。
受试者/方法:使用高效液相色谱法对203例接受华法林治疗的房颤门诊患者的302份血浆维生素K浓度进行了评估。回顾性分析了包括华法林剂量、血浆华法林浓度、凝血酶原时间国际标准化比值(PT INR)和CYP2C9/VKORC1基因型在内的临床和实验室信息。对163例长期接受华法林治疗的患者的抗凝稳定性(个体内变异性、PT INR检测频率和并发症)进行了研究。测定了40名健康受试者以及40例患者在初始华法林治疗前后的血浆维生素K水平。
华法林治疗开始后维生素K浓度显著降低(治疗前:1.72 ng/ml;治疗后:0.59 ng/ml,P<0.05)。接受华法林治疗的患者维生素K水平存在较大的个体间变异性(0.2 - 4.2 ng/ml)。血浆维生素K水平低的患者比维生素K水平高的患者更频繁地检查PT INR(每年9.5次 vs 每年7.5次,P = 0.029)。两名出现肉眼血尿的患者维生素K水平极低(<0.4 ng/ml)。
我们发现接受华法林治疗的患者维生素K浓度存在较高的个体间和个体内变异性。接受华法林治疗的患者维生素K浓度低表明饮食限制过度。测定血浆维生素K水平有助于饮食控制和抗凝稳定性。